| 0 (0%) | 01-19 20:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.97 | 1-year : | 48.7 |
| Resists | First : | 40.22 | Second : | 41.7 |
| Pivot price | 39.8  |
|||
| Supports | First : | 37.83 | Second : | 31.47 |
| MAs | MA(5) : | 40.02 |
MA(20) : | 39.57 |
| MA(100) : | 37.79 |
MA(250) : | 35.37 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45 |
D(3) : | 52.2 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 41.7 | Low : | 29.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RPRX ] has closed above bottom band by 41.5%. Bollinger Bands are 22.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.86 - 40.1 | 40.1 - 40.28 |
| Low: | 38.77 - 39.09 | 39.09 - 39.33 |
| Close: | 39.13 - 39.6 | 39.6 - 39.95 |
Fri, 16 Jan 2026
Interesting RPRX Call Options For March 20th - Nasdaq
Thu, 15 Jan 2026
Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wed, 14 Jan 2026
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Tue, 13 Jan 2026
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Mon, 12 Jan 2026
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Zacks Investment Research
Mon, 12 Jan 2026
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 427 (M) |
| Shares Float | 375 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 81.9 (%) |
| Shares Short | 27,720 (K) |
| Shares Short P.Month | 24,030 (K) |
| EPS | 1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.94 |
| Profit Margin | 32.5 % |
| Operating Margin | 70.2 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 13.1 % |
| Qtrly Rev. Growth | 7.9 % |
| Gross Profit (p.s.) | 5.85 |
| Sales Per Share | 5.5 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -45.3 % |
| Operating Cash Flow | 2,410 (M) |
| Levered Free Cash Flow | -591 (M) |
| PE Ratio | 22.6 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 7.19 |
| Price to Cash Flow | 7.01 |
| Dividend | 0.21 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|